Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

Open Access Highly Accessed Commentary

Detection of a gammaretrovirus, XMRV, in the human population: Open questions and implications for xenotransplantation

Joachim Denner

Author Affiliations

Retrovirus induced immunosuppression, Robert Koch Institute, Nordufer 20, D-13353 Berlin, Germany

Retrovirology 2010, 7:16  doi:10.1186/1742-4690-7-16

The electronic version of this article is the complete one and can be found online at: http://www.retrovirology.com/content/7/1/16


Received:4 December 2009
Accepted:10 March 2010
Published:10 March 2010

© 2010 Denner; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

XMRV (xenotropic murine leukaemia virus-related virus) is a gammaretrovirus that has been detected in human patients with prostate carcinoma, chronic fatigue syndrome (CFS) and also in a small percentage of clinically healthy individuals. It is not yet clear whether the distribution of this virus is primarily limited to the USA or whether it is causally associated with human disease. If future investigations confirm a broad distribution of XMRV and its association with disease, this would have an impact on xenotransplantation of porcine tissues and organs. Xenotransplantation is currently being developed to compensate for the increasing shortage of human material for the treatment of tissue and organ failure but could result in the transmission of porcine pathogens. Maintenance of pathogen-free donor animals will dramatically reduce this risk, but some of the porcine endogenous retroviruses (PERVs) found in the genome of all pigs, can produce infectious virus and infect cultured human cells. PERVs are closely related to XMRV so it is critical to develop tests that discriminate between them. Since recombination can occur between viruses, and recombinants can exhibit synergism, recipients should be tested for XMRV before xenotransplantation.

Questions concerning XMRV detection

XMRV was first detected in prostate carcinomas of patients who were homozygous for a mutation in the gene for the antiviral enzyme, ribonuclease L (RNase L) [1]. Men with two copies of the homozygous mutation R462Q (QQ) were found to have twice the risk of prostate cancer as males with the non-mutated allele. Integrated XMRV was detected in 8 of 20 of these patients (40%) using a DNA microarray and RT-PCR analysis. In heterozygous patients and patients without the mutation, XMRV was found only in 1.5% of prostate tumours. The sequence of the virus is closely related (more than 93% DNA sequence identity) to other xenotropic murine retroviruses. Xenotropic viruses infect only cells from other species. Interestingly, low levels of XMRV protein expression were detected in a small number of stromal cells, but not in the tumour cells themselves. In vitro tests have revealed that the virus productively infects human cells and that its replication is susceptible to IFN-β treatment [2]. Another study identified XMRV proviral DNA in 6% of the prostate tumours analysed by real time PCR and viral protein was detected in 23% of 334 prostate tumours using antisera against a panel of murine retroviruses including XMRV [3]. In that study, infection was associated with high-grade tumours, but did not correlate with the RNase L QQ variant. In contrast to previous reports [1], XMRV proteins were found to be expressed primarily in tumour cells [3]. Unfortunately screening for XMRV specific antibodies was not performed, although it is generally agreed that detection of antibodies is a common and reliable diagnostic method to detect low level infections with retroviruses including HIV-1. In cases of low proviral load, antibody detection can indicate infection in the absence of positive PCR results [4].

In Europe, XMRV appears to be less common than in the USA. No XMRV was found in 139 Irish prostate cancer patients with the RNase L mutation [5]. In a German study, XMRV-specific sequences were detected in only in 1 of 105 tissue samples from non-familial prostate cancer and in 1 of 70 tissue samples from men without prostate cancer [6]. The two positive samples were not correlated with homozygosity for the R462Q mutation. In a larger study, Hohn et al. [6] failed to find any XMRV-specific sequences in the DNA and RNA from tumours of 589 German prostate cancer patients, even though 12.9% of them were shown to be of the QQ genotype [7]. Most importantly, we did not find antibodies when sera from 146 patients from this cohort were tested [7].

A recent study in the USA identified XMRV-specific proviral DNA in PBMCs from patients suffering from chronic fatigue syndrome (CFS) [8]. CSF is characterized by debilitating fatigue, chronic inflammation and other abnormalities of the immune system such as a deficiency in natural killer cell activity. In 68 of 101 CFS patients (67%), but also in 8 of 218 (3.7%) healthy controls, XMRV could be detected by PCR [8]. This 3.7% incidence in healthy controls suggests that several million Americans may be infected. Laboratory tests revealed that virus from patient-derived sera could infect cultured human cells. The authors detected antiviral antibodies in 9 out of 18 patients using a test based on an envelope protein from spleen focus forming virus which is closely related to XMRV. In contrast, two other studies found no XMRV in clinically well-characterized European CFS patients [9,10]. In one of these studies, PCR analysis revealed no XMRV DNA in 299 samples, although some serum samples showed XMRV neutralising activity. Only one of these was from a CFS patient [9]. In the other study, neither XMRV nor murine leukemia virus sequences were detected. The authors came to the conclusion the XMRV is not a contributory factor in the pathogenesis of CSF [10].

In light of these results, the finding of XMRV in prostate tumours and CFS patients in the USA has to be treated with great caution. In the past, numerous retroviruses have been reported in human tissues and cultured cells (for review see [11]). Some of these have later been shown to be contaminating animal viruses with unknown origin and function. Only HIV-1 and HIV-2, both of which induce acquired immunodeficiency syndromes (AIDS), and the human T-lymphotropic viruses, HTLV-1 and HTLV-2, which induce adult T-cell leukaemia and HTLV-associated myelopathy/tropical spastic paraperesis, have been proven to be linked to human diseases. Highly sensitive methods such as PCR allow detection of minimal traces of retroviruses but also detect sample contamination. Indeed, contaminating retroviruses, mainly gammaretroviruses, have been found in numerous human cell lines (for literature see the latest report concerning this topic, [12]).

Trans-species transmission of retroviruses has occurred frequently during evolution (for review see [13]), and HIV-1 is the best-known example. Trans-species transmission has also been reported for gammaretroviruses closely related to XMRV, for example the Koala retrovirus [14]. Important questions remain to be answered: How and when did this murine xenotropic virus infect humans? Is it a direct infection from rodents to susceptible humans or is the virus spreading through human populations resulting in high virus load in (immunosuppressed) tumours and CFS patients? Is a third species transmitting the virus from mice to humans? As mentioned above, 3.7% of healthy controls from one study in the USA were virus positive [3]. Why is the virus common in the USA but rare in Europe? Are there specific populations of rodents in the USA releasing this virus? Why is disease associated with XMRV in the USA but not in Europe? Is XMRV a passenger virus replicating in immuno-compromised individuals or does this virus contribute directly to disease progression? The immunosuppressive properties characteristic of all retroviruses [15] could contribute to tumour progression as well as to the symptoms of CSF. If XMRV is indeed widely distributed in the human population and associated with tumours and CSF, should blood donors be tested in order to avoid XMRV transmission?

PERVs, XMRV and possible implications for xenotransplantation

With so many unanswered questions, much work remains to be done. At this early point in XMRV research, areas should be identified in which this virus may cause a serious impact on human health. One of these areas may be the xenotransplantation of porcine tissues and organs to humans. Xenotransplantation is a potential solution for the shortage of allogeneic human organs. Designated pathogen-free breeding and maintenance of pigs can prevent the transmission of most porcine pathogens; however, porcine endogenous retroviruses (PERVs) are integrated in the pig genome and can be released from normal pigs and infect human cells in vitro [16,17]. In the past, highly sensitive methods had been developed to detect PERV infection. A PCR study of more than 200 patients treated with pig material for PERV transmission found no viral DNA [18]. However, three of the patients showed a clear antibody response against the p27Gag of PERV in a Western blot assay, and a small percentage of blood donors (5%) have also been found to react with the p27Gag of PERV [18,19]. Since antibodies against the Env protein of PERV were not found, this reaction was classified as not specific for PERV following the rules applied for HIV-1 diagnostic tests. Is it possible that the antibody response detected was against a related retrovirus such as XMRV?

If XMRV is indeed circulating in the human population, it has important implications for xenotransplantation. A test should be developed to discriminate between PERV and XMRV, and the potential for recombination between the two viruses should be investigated. Recombination between the human tropic PERV-A and the ecotropic PERV-C has been described in normal pigs and in melanoma-bearing animals, and recombinant PERV-A/C was characterized by high replication titers [20-22]. Whether XMRV and PERV recombine remains unclear, however co-packaging [23] and pseudotyping [24] between PERV and murine retroviruses have been described. Although the sequence identity between PERV and XMRV is only approximately 53%, there are regions with higher homology that would allow recombination.

This raises new questions: Should the xenotransplant recipients be pre-screened for XMRV to avoid recombination? What measures can be taken when XMRV infection is detected in such a screen? Before dealing with these specific details, it is necessary to address the important broad questions concerning the distribution of XMRV and its impact on human health.

Competing interests

The author declares that he has no competing interests.

Added in proof

In a recent case-control study van Kuppeveld et al. [25] detected no XMRV sequences in any of the Dutch patients with CFS or controls.

Acknowledgements

I thank Joseph W. Carnwath for critical reading of the manuscript.

References

  1. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K, Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL: Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant.

    PLoS Pathog 2006, 2(3):e25. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  2. Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Ganem D, Derisi JL, Chow SA, Silverman RH: An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.

    Proc Natl Acad Sci USA 2007, 104(5):1655-1660. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  3. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR: XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors.

    Proc Natl Acad Sci USA 2009, 106(38):16351-16356. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  4. Fiebig U, Hartmann MG, Bannert N, Kurth R, Denner J: Transspecies transmission of the endogenous koala retrovirus (KoRV).

    J Virol 2006, 80(11):5651-5654. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  5. D'Arcy F, Foley R, Perry A, Marignol L, Lawler M, Gaffney E, Watson RGW, Fitzpatrick JM, Lynch TH: No evidence of XMRV in irish prostate cancer patients with the R462Q mutation.

    European Urology Supplements 2008, 7:271. Publisher Full Text OpenURL

  6. Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H, Aepfelbacher M, Schlomm T: Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer.

    J Clin Virol 2008, 43(3):277-283. PubMed Abstract | Publisher Full Text OpenURL

  7. Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N, Denner J, Miller K, Kurth R, Bannert N: Lack of evidence for XMRV in prostate cancer biopsies from German patients.

    Retrovirology 2009, 6(1):92. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  8. Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH, Mikovits JA: Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome.

    Science 2009, 326:585-589. PubMed Abstract | Publisher Full Text OpenURL

  9. Groom HC, Boucherit VC, Makinson K, Randal E, Baptista S, Hagan S, Gow JW, Mattes FM, Breuer J, Kerr JR, Stoye JP, Bishop KN: Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome.

    Retrovirology 2010, 7(1):10. PubMed Abstract | BioMed Central Full Text OpenURL

  10. Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S, Cleare A: Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome.

    PLoS One 2010, 5(1):e8519. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  11. Voisset C, Weiss RA, Griffiths DJ: Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease.

    Microbiol Mol Biol Rev 2008, 72(1):157-1596. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  12. Takeuchi Y, McClure MO, Pizzato M: Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research.

    J Virol 2008, 82(24):12585-8. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  13. Denner J: Transspecies transmissions of retroviruses: New cases.

    Virology 2007, 369:229-233. PubMed Abstract | Publisher Full Text OpenURL

  14. Tarlinton RE, Meers J, Young PR: Retroviral invasion of the koala genome.

    Nature 2006, 442(7098):79-81. PubMed Abstract | Publisher Full Text OpenURL

  15. Denner J: Immunosuppression by retroviruses: implications for xenotransplantation.

    Ann NY Acad Sci 1998, 862:75-86. PubMed Abstract | Publisher Full Text OpenURL

  16. Scobie L, Takeuchi Y: Porcine endogenous retrovirus and other viruses in xenotransplantation.

    Curr Opin Organ Transplant 2009, 14(2):175-179. PubMed Abstract | Publisher Full Text OpenURL

  17. Wilson CA: Porcine endogenous retroviruses and xenotransplantation.

    Cell Mol Life Sci 2008, 65(21):3399-3412. PubMed Abstract | Publisher Full Text OpenURL

  18. Paradis K, Langford G, Long Z, Heneine W, Sandstrom P, Switzer WM, Chapman LE, Lockey C, Onions D, Otto E: Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group.

    Science 1999, 285(5431):1236-1241. PubMed Abstract | Publisher Full Text OpenURL

  19. Tacke S, Bodusch K, Berg A, Denner J: Sensitive and specific immunological detection methods for porcine endogenous retroviruses applicable to experimental and clinical xenotransplantation.

    Xenotransplantation 2001, 8:125-135. PubMed Abstract | Publisher Full Text OpenURL

  20. Denner J: Recombinant porcine endogenous retroviruses (PERV-A/C): A new risk for xenotransplantation?

    Arch Virol 2008, 153:1421-1426. PubMed Abstract | Publisher Full Text OpenURL

  21. Dieckhoff B, Puhlmann J, Büscher K, Hafner-Marx A, Herbach N, Bannert N, Büttner M, Wanke R, Kurth R, Denner J: Expression of porcine endogenous retroviruses (PERVs) in melanomas of Munich miniature swine (MMS) Troll.

    Vet Microbiol 2007, 20;123(1-3):53-68. Publisher Full Text OpenURL

  22. Martin SI, Wilkinson R, Fishman JA: Genomic presence of recombinant porcine endogenous retrovirus in transmitting miniature swine.

    Virol J 2006, 3:91. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  23. Suling K, Quinn G, Wood J, Patience C: Packaging of human endogenous retrovirus sequences is undetectable in porcine endogenous retrovirus particles produced from human cells.

    Virology 2003, 312(2):330-336. PubMed Abstract | Publisher Full Text OpenURL

  24. Martina Y, Kurian S, Cherqui S, Evanoff G, Wilson C, Salomon DR: Pseudotyping of porcine endogenous retrovirus by xenotropic murine leukemia virus in a pig islet xenotransplantation model.

    Am J Transplant 2005, 5(8):1837-47. PubMed Abstract | Publisher Full Text OpenURL

  25. Kuppeveld FJM, de Jong AS, Lanke KH, Verhaegh GW, Melchers WJG, Swanink CMA, Bleijenberg G, Netea MG, Galama JMD, Meer JWM: Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort.

    BMJ 2010, 340:c1018. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL